{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T19:53:20Z","timestamp":1785873200700,"version":"3.56.0"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The treatment outcomes of inflammatory bowel disease (IBD) have been significantly improved by the advent of new biologics, including ulcerative colitis (UC) and Crohn\u2019s disease (CD), particularly for refractory cases. However, the growing number of therapeutic options has also complicated clinical decision-making regarding drug selection and switching. The overall performance of IL-23 p19 inhibitors for the treatment of IBD was evaluated by the systematic review and meta-analysis in this study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>The objective of this study was to combine the multiple indicators to accurately evaluate the efficacy and safety of IL-23 p19 inhibitors, aimed to offer an insight into the development of clinical physicians\u2019 medication.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A comprehensive literature review on PubMed, Embase, Web of Science, and Cochrane Library until June 2024 was conducted in this study, which mainly focused on the randomized controlled trials (RCTs) to evaluate the IL-23 p19 inhibitors within adult patients with UC or CD. Additionally, the clinical outcomes, endoscopic findings, histological assessments, and safety profiles were aggregated and subjected to analysis by a random-effects model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty-five RCTs [15 CD, 10 UC] were involved in this study, and it was revealed that IL-23 p19 inhibitors showed significant effects on clinical remission (CR) in IBD, regardless of induction or maintenance treatment (CD, induction: risk ratio [RR] 1.95, 95% confidence interval [CI] 1.71\u20132.23; I<jats:sup>2<\/jats:sup> = 0%, p = 0.68; UC, induction: RR 2.69, 95% CI 1.80\u20134.03; I<jats:sup>2<\/jats:sup> = 50%, p = 0.09; CD, maintenance: RR 1.24, 95% CI 1.04\u20131.48; I<jats:sup>2<\/jats:sup> = 0%, p = 0.57; UC, maintenance: RR 2.62, 95% CI 0.92\u20137.49; I<jats:sup>2<\/jats:sup> = 42%, p = 0.19), and the risk of adverse events (AEs) was similar to that of placebo (CD, induction: RR 0.88, 95% CI 0.82\u20130.94; I<jats:sup>2<\/jats:sup> = 2%, p = 0.41; UC, induction: RR 0.92, 95% CI 0.82\u20131.03; I<jats:sup>2<\/jats:sup> = 0%, p = 0.54; CD, maintenance: RR 1.00, 95% CI 0.89\u20131.13; I<jats:sup>2<\/jats:sup> = 29%, p = 0.25; UC, maintenance: RR 0.96, 95% CI 0.87\u20131.06; I<jats:sup>2<\/jats:sup> = 0%, p = 0.44).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In IBD treatment, IL-23 p19 inhibitor therapy exhibited effective functions in the inducement and maintenance of clinical and endoscopic remissions, as well as in some histological cases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic Review Registration<\/jats:title><jats:p>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD42024569807, identifier CRD42024569807<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1490667","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T06:08:35Z","timestamp":1745820515000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy and safety of IL-23 p19 inhibitors in the treatment for inflammatory bowel disease: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Shuhan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study","volume":"77","author":"Baeten","year":"2018","journal-title":"Ann. Rheumatic Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1053\/j.gastro.2024.05.036","article-title":"Targeting the interleukin 23 pathway in inflammatory bowel disease","volume":"168","author":"Bourgonje","year":"2024","journal-title":"Gastroenterology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"765474","DOI":"10.3389\/fmed.2021.765474","article-title":"Treatment of inflammatory bowel disease: a comprehensive review","volume":"8","author":"Cai","year":"2021","journal-title":"Front. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1002\/ijc.31407","article-title":"Tumor necrosis factor-alpha inhibitors and risk of non-Hodgkin lymphoma in a cohort of adults with rheumatologic conditions","volume":"143","author":"Calip","year":"2018","journal-title":"Int. J. Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.14309\/ajg.0000000000001396","article-title":"A comprehensive literature review and expert Consensus statement on therapeutic drug monitoring of biologics in inflammatory bowel disease","volume":"116","author":"Cheifetz","year":"2021","journal-title":"Am. J. Gastroenterology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S2468-1253(23)00318-7","article-title":"Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial","volume":"9","author":"Danese","year":"2024","journal-title":"Lancet Gastroenterology Hepatology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as induction and maintenance therapy for ulcerative colitis","volume":"388","author":"D'Haens","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","article-title":"Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials","volume":"399","author":"D'Haens","year":"2022","journal-title":"Lancet London, Engl."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1053\/j.gastro.2021.06.037","article-title":"775a risankizumab induction therapy in patients with moderate-to-severe Crohn\u2019s disease with intolerance or inadequate response to conventional and\/or biologic therapy: results from the phase 3 ADVANCE study","volume":"161","author":"D'Haens","year":"","journal-title":"Gastroenterology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/s0016-5085(21)00960-4","article-title":"455 the effect of guselkumab induction therapy on endoscopic outcome measures in patients with moderately to severely active crohn's disease: Week 12 Results Phase 2 Galaxi 1 Study","volume":"160","author":"D'Haens","year":"","journal-title":"Gastroenterology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1016\/S0140-6736(17)30570-6","article-title":"Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study","volume":"389","author":"Feagan","year":"2017","journal-title":"Lancet London, Engl."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(22)00466-4","article-title":"Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial","volume":"399","author":"Ferrante","year":"2022","journal-title":"Lancet London, Engl."},{"key":"B13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/jgh.16358","article-title":"Efficacy and safety of risankizumab for Crohn's disease in patients from Asian countries: a post hoc subanalysis of the global phase 3 ADVANCE, MOTIVATE, and FORTIFY studies","volume":"39","author":"Gao","year":"2024","journal-title":"J. Gastroenterology Hepatology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.jhsa.2020.03.016","article-title":"Understanding PROMIS","volume":"45","author":"Hammert","year":"2020","journal-title":"J. Hand Surg."},{"key":"B15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41575-020-00360-x","article-title":"The four epidemiological stages in the global evolution of inflammatory bowel disease","volume":"18","author":"Kaplan","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"455","DOI":"10.5009\/gnl16308","article-title":"Inflammatory bowel disease: updates on molecular targets for biologics","volume":"11","author":"Katsanos","year":"2017","journal-title":"Gut Liver"},{"key":"B17","doi-asserted-by":"publisher","first-page":"172","DOI":"10.5217\/ir.2023.00043","article-title":"Efficacy and safety of mirikizumab as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a subgroup analysis of the global phase 3 LUCENT-1 and LUCENT-2 studies","volume":"22","author":"Kobayashi","year":"2024","journal-title":"Intestinal Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.molmed.2023.01.001","article-title":"IBD disease-modifying therapies: insights from emerging therapeutics","volume":"29","author":"Kotla","year":"2023","journal-title":"Trends Mol. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1136\/gutjnl-2014-309014","article-title":"Tissue-infiltrating neutrophils represent the main source of IL-23 in the colon of patients with IBD","volume":"65","author":"Kvedaraite","year":"2016","journal-title":"Gut"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1053\/j.gastro.2023.07.003","article-title":"Incidence, prevalence, and racial and ethnic distribution of inflammatory bowel disease in the United States","volume":"165","author":"Lewis","year":"2023","journal-title":"Gastroenterology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cytogfr.2023.07.001","article-title":"Recent advances in the treatment of IBD: targets, mechanisms and related therapies","author":"Liu","year":"2023","journal-title":"Cytokine Growth Factor Rev."},{"key":"B22","doi-asserted-by":"publisher","first-page":"S624","DOI":"10.14309\/01.ajg.0000953020.05891.05","article-title":"S845 risankizumab induction therapy in patients with moderately to severely active ulcerative colitis: efficacy and safety in the randomized phase 3 INSPIRE","volume":"118","author":"Louis","year":"2023","journal-title":"Study"},{"key":"B23","doi-asserted-by":"publisher","first-page":"106146","DOI":"10.1016\/j.phrs.2022.106146","article-title":"Emerging pharmacotherapy for inflammatory bowel diseases","volume":"178","author":"Luo","year":"2022","journal-title":"Pharmacol. Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jmb.2008.07.051","article-title":"The structure of interleukin-23 reveals the molecular basis of p40 subunit sharing with interleukin-12","volume":"382","author":"Lupardus","year":"2008","journal-title":"J. Mol. Biol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"581","DOI":"10.2217\/imt-2023-0219","article-title":"Positioning risankizumab in the treatment algorithm of moderate-to-severe Crohn's disease","volume":"16","author":"Lusetti","year":"2024","journal-title":"Immunotherapy"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1093\/ecco-jcc\/jjad050","article-title":"Resolving histological inflammation in ulcerative colitis with mirikizumab in the LUCENT induction and maintenance trial programmes","volume":"17","author":"Magro","year":"","journal-title":"J. Crohn\u2019s Colitis"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1016\/j.cgh.2023.11.010","article-title":"Effects of mirikizumab on histologic resolution of crohn's disease in a randomized controlled phase 2 trial","volume":"22","author":"Magro","year":"","journal-title":"Clin. Gastroenterology Hepatology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/s1074-7613(00)00070-4","article-title":"Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12","volume":"13","author":"Oppmann","year":"2000","journal-title":"Immunity"},{"key":"B29","doi-asserted-by":"publisher","first-page":"S404","DOI":"10.1093\/ecco-jcc\/jjab076.519","article-title":"P395 Impact of mirikizumab therapy on histologic measures of intestinal inflammation in a Phase 2 study of patients with moderately to severely active Crohn\u2019s disease","volume":"15","author":"Pai","year":"2021","journal-title":"J. Crohn\u2019s Colitis"},{"key":"B30","doi-asserted-by":"publisher","first-page":"S348","DOI":"10.14309\/01.ajg.0000776548.94565.6c","article-title":"S754 risankizumab as induction therapy in patients with moderately to severely active Crohn\u2019s disease who failed 1 vs >1 prior biologic treatment: results from the MOTIVATE study","volume":"116","author":"Panaccione","year":"2021","journal-title":"J. Am. Coll. Gastroenterology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1053\/j.gastro.2023.08.038","article-title":"Guselkumab in patients with moderately to severely active ulcerative colitis: QUASAR phase 2b induction study","volume":"165","author":"Peyrin-Biroulet","year":"2023","journal-title":"Gastroenterology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1053\/j.gastro.2019.04.016","article-title":"Environmental risk factors for inflammatory bowel diseases: an umbrella review of meta-analyses","volume":"157","author":"Piovani","year":"2019","journal-title":"Gastroenterology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/MOG.0000000000000607","article-title":"Safety considerations with biologics and new inflammatory bowel disease therapies","volume":"36","author":"Queiroz","year":"2020","journal-title":"Curr. Opin. Gastroenterology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet London, Engl."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1038\/ctg.2015.63","article-title":"Loss of response to anti-TNFs: definition, epidemiology, and management","volume":"7","author":"Roda","year":"2016","journal-title":"Clin. Transl. Gastroenterology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.3390\/ijms24021526","article-title":"Pathophysiology of inflammatory bowel disease: innate immune system","volume":"24","author":"Saez","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1053\/j.gastro.2022.01.047","article-title":"Guselkumab for the treatment of crohn's disease: induction results from the phase 2 GALAXI-1 study","volume":"162","author":"Sandborn","year":"2022","journal-title":"Gastroenterology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1053\/j.gastro.2019.08.043","article-title":"Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1053\/j.gastro.2017.03.049","article-title":"Efficacy and safety of MEDI2070, an antibody against interleukin 23, in patients with moderate to severe crohn's disease: a phase 2a study","volume":"153","author":"Sands","year":"2017","journal-title":"Gastroenterology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1053\/j.gastro.2021.10.050","article-title":"Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with crohn's disease","volume":"162","author":"Sands","year":"2022","journal-title":"Gastroenterology"},{"key":"B41","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41573-022-00557-6","article-title":"Emerging principles of cytokine pharmacology and therapeutics","volume":"22","author":"Saxton","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"B42","doi-asserted-by":"publisher","first-page":"622934","DOI":"10.3389\/fimmu.2021.622934","article-title":"Role of the IL23\/IL17 pathway in crohn's disease","volume":"12","author":"Schmitt","year":"2021","journal-title":"Front. Immunol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.3748\/wjg.v29.i18.2733","article-title":"Study of tumor necrosis factor receptor in the inflammatory bowel disease","volume":"29","author":"Souza","year":"2023","journal-title":"World J. Gastroenterology"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e200","DOI":"10.1016\/S2589-7500(21)00292-2","article-title":"Advancing digital health applications: priorities for innovation in real-world evidence generation","volume":"4","author":"Stern","year":"2022","journal-title":"Lancet Digital Health"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1172\/JCI21404","article-title":"IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6","volume":"116","author":"Yen","year":"2006","journal-title":"J. Clin. Investigation"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1186\/s12889-023-17431-8","article-title":"Trends and projections of inflammatory bowel disease at the global, regional and national levels, 1990-2050: a bayesian age-period-cohort modeling study","volume":"23","author":"Zhou","year":"2023","journal-title":"BMC Public Health"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1490667\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T06:08:36Z","timestamp":1745820516000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1490667\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":46,"alternative-id":["10.3389\/fphar.2025.1490667"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1490667","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,28]]},"article-number":"1490667"}}